Company / SG&A per Share
Jazz Pharmaceuticals SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$29.84
FY2025
5-year range
$13.12 / $29.84
FY2021-FY2025
Trend
+34.1%
vs FY2024
Sector context
#4 of 210
Health Care
What the data says
Among 210 Health Care companies, Jazz Pharmaceuticals is in the bottom 2% for sg&a per share. SG&A per Share has increased for 7 consecutive years, from $8.54 in FY2018 to $29.84 in FY2025.
Based on SEC 10-K filings.
29.84 in FY2025 with a 5-year CAGR of +19.6%. Top quartile in the Health Care sector.
Increased from $21.25 to $29.84 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +29.1%
- 5-Year CAGR
- +19.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 210This company $29.84 Sector average $29.50
▼
+1.1% above sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's sg&a per share has grown for 7 consecutive years.
- In FY2025, sg&a per share increased 34.1% year-over-year.
- Ranks #4 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.84 | +34.1% |
| FY2024 | $22.25 | +4.7% |
| FY2023 | $21.25 | +53.3% |
| FY2022 | $13.86 | +5.6% |
| FY2021 | $13.12 | +7.8% |
| FY2020 | $12.18 | +29.1% |
| FY2019 | $9.43 | +10.4% |
| FY2018 | $8.54 | -6.1% |
| FY2017 | $9.10 | +37.3% |
| FY2016 | $6.62 | -10.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026